AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36909596 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention (TBRI) Caregiver Training
Number of subjects: 0
Study 36909731 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Number of subjects: 34
Study 36909845 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 878
Study 36909845 — intervention group
Group type: COMPARATOR
Intervention: Culture-based methods
Number of subjects: 878
Study 36909848 — intervention group
Group type: EXPERIMENTAL
Intervention: CV Wizard system
Number of subjects: 17931
Study 36909865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFEM+RF procedure (four, 30-minute bilateral procedures over the upper arms spaced one week apart)
Number of subjects: 34
Study 36910109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 90
Study 36910109 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 90
Study 36910250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sleep audio or visual alpha entrainment for 30 minutes each night for 4 weeks
Number of subjects: 28
Study 36910457 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary L-type fatty acid-binding protein (L-FABP) measured within 48 hours of admission
Number of subjects: 224
Study 36910457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-FABP point of care (POC) test
Number of subjects: 224
Study 36910479 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda
Number of subjects: 14
Study 36910479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 36910501 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Number of subjects: 160
Study 36910501 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Number of subjects: 160
Study 36910501 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 160
Study 36910501 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 160
Study 36910518 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention (PCI) with 3-month follow-up OCT imaging (O3 group)
Number of subjects: 60
Study 36910518 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discontinuation of dual antiplatelet therapy (DAPT)
Number of subjects: 60
Study 36910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shock-wave therapy (CSWT)
Number of subjects: 72
Study 36910537 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 72
Study 36910599 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based risk score
Number of subjects: 78
Study 36910599 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating radiomics data, clinical data, and TNM information
Number of subjects: 78
Study 36910599 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 78
Study 36910668 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiles
Number of subjects: 27
Study 36910693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily for 48 weeks
Number of subjects: 43
Study 36911033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone locomotor training using a robotic crawl training device from 5 to 9 months of age
Number of subjects: 60
Study 36911033 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright locomotor training using a dynamic weight support system from 9 to 18 months of age
Number of subjects: 60
Study 36911033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early spontaneous leg movements measured monthly from 1 to 4 months of age using inertial sensors
Number of subjects: 60
Study 36911725 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG1- and PD-L1-derived peptide vaccination with Montanide ISA-51 as adjuvant
Number of subjects: 9
Study 36911944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal onasemnogene abeparvovec (medium dose)
Number of subjects: 32
Study 36911951 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual sensory integration training in virtual reality
Number of subjects: 30
Study 36911951 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional vestibular rehabilitation
Number of subjects: 30
Study 36911951 — intervention group
Group type: COMPARATOR
Intervention: Controls (no intervention)
Number of subjects: 30
Study 36912033 — intervention group
Group type: EXPERIMENTAL
Intervention: Total aortic arch replacement
Number of subjects: 3902
Study 36912033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic root replacement
Number of subjects: 3902
Study 36912033 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 3902
Study 36912078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib plus durvalumab
Number of subjects: 0
Study 36912144 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (1 mA for 20 minutes) plus fifteen 45-minute sessions of naming treatment
Number of subjects: 58
Study 36912144 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS plus fifteen 45-minute sessions of naming treatment
Number of subjects: 58
Study 36912144 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 58
Study 36912144 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 58
Study 36912172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF)
Number of subjects: 136
Study 36912172 — intervention group
Group type: COMPARATOR
Intervention: Baseline regimens
Number of subjects: 136
Study 36912439 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate operation (IOP)
Number of subjects: 1177
Study 36912439 — intervention group
Group type: COMPARATOR
Intervention: Delayed operation after active surveillance (DOP)
Number of subjects: 1177
Study 36912439 — intervention group
Group type: COMPARATOR
Intervention: Delayed operation after active surveillance (DOP) with disease progression
Number of subjects: 1177
Study 36912445 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized low-calorie diet with calorie intake equalling their basal requirement along with exercise for 2 weeks before surgery
Number of subjects: 62
Study 36912445 — intervention group
Group type: COMPARATOR
Intervention: Normal routine lifestyle
Number of subjects: 62
Study 36912484 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 168
Study 36912484 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 168
Study 36912538 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study 36912538 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 1643
Study 36912538 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study 36912566 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CABG with DuraGraft intraoperatively for conduit preservation
Number of subjects: 2532
Study 36912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (LPD)
Number of subjects: 1029
Study 36912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated pancreatic duct (>3 mm)
Number of subjects: 1029
Study 36912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age (≥75 years)
Number of subjects: 1029
Study 36912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cardiovascular disease
Number of subjects: 1029
Study 36912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital volume, surgeon's experience with open pancreaticoduodenectomy and minimally invasive surgery, surpassing the LPD learning curve
Number of subjects: 1029
Study 36912568 — intervention group
Group type: COMPARATOR
Intervention: Different hospitals
Number of subjects: 1029
Study 36912740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-PRESS plus trabeculectomy
Number of subjects: 961
Study 36912740 — intervention group
Group type: EXPERIMENTAL
Intervention: PreserFlo MicroShunt
Number of subjects: 961
Study 36912740 — intervention group
Group type: COMPARATOR
Intervention: Device-modified trabeculectomy
Number of subjects: 961
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivascular endothelial growth factors
Number of subjects: 0
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 0
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: New intravitreal drugs
Number of subjects: 0
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0
Study 36912792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive (sometimes surgical) approach
Number of subjects: 0
Study 36912809 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy or chemo-immunotherapy
Number of subjects: 0
Study 36912809 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36912897 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 36912897 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36913051 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN1611
Number of subjects: 0
Study 36913051 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN1611 + trastuzumab
Number of subjects: 0
Study 36913051 — intervention group
Group type: COMPARATOR
Intervention: taselisib
Number of subjects: 0
Study 36913051 — intervention group
Group type: COMPARATOR
Intervention: alpelisib
Number of subjects: 0
Study 36913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 120
Study 36913378 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 120
Study 36913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self-compassionate mental imagery instructions
Number of subjects: 120
Study 36913378 — intervention group
Group type: COMPARATOR
Intervention: Sham mental imagery instructions
Number of subjects: 120
Study 36913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 120
Study 36913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking task
Number of subjects: 120
Study 36913433 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CL Detect Rapid Test (increased extraction time and sample volume)
Number of subjects: 156
Study 36913433 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 156
Study 36913433 — intervention group
Group type: COMPARATOR
Intervention: kDNA-PCR
Number of subjects: 156
Study 36913444 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosaccharide intake
Number of subjects: 0
Study 36913446 — intervention group
Group type: EXPERIMENTAL
Intervention: 85%-HAF bread
Number of subjects: 20
Study 36913446 — intervention group
Group type: EXPERIMENTAL
Intervention: 70%-HAF bread
Number of subjects: 20
Study 36913446 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 20
Study 36913449 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg introduction during infancy
Number of subjects: 1089
Study 36913483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruitflow (water-soluble tomato extract)
Number of subjects: 22
Study 36913518 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication intake
Number of subjects: 0
Study 36913642 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 55
Study 36913642 — intervention group
Group type: EXPERIMENTAL
Intervention: RPLND
Number of subjects: 55
Study 36913694 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 30
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed infant formula
Number of subjects: 73
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and juices
Number of subjects: 73
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 73
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats
Number of subjects: 73
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 73
Study 36913717 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes
Number of subjects: 73
Study 36913959 — intervention group
Group type: COMPARATOR
Intervention: Monthly IPTp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day)
Number of subjects: 4680
Study 36913959 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly IPTp with dihydroartemisinin-piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days)
Number of subjects: 4680
Study 36913959 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly IPTp with dihydroartemisinin-piperaquine plus azithromycin (two tablets containing 500 mg once daily for 2 consecutive days)
Number of subjects: 4680
Study 36914049 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 227
Study 36914049 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 227
Study 36914185 — intervention group
Group type: EXPERIMENTAL
Intervention: COPDPredict with rescue medication (RM)
Number of subjects: 384
Study 36914185 — intervention group
Group type: COMPARATOR
Intervention: Standard self-management plans with rescue medication (RM)
Number of subjects: 384
Study 36914193 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant arterial embolisation chemotherapy (NAEC) with oxaliplatin 85 mg/m²
Number of subjects: 0
Study 36914233 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher transcutaneous carbon dioxide targeting 5 mm Hg (0.67 kPa) changes
Number of subjects: 25
Study 36914233 — intervention group
Group type: COMPARATOR
Intervention: Lower transcutaneous carbon dioxide targeting 5 mm Hg (0.67 kPa) changes
Number of subjects: 25
Study 36914591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 4 mg once daily for 8 days
Number of subjects: 48
Study 36914591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 8 mg once daily for 8 days
Number of subjects: 48
Study 36914591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 16 mg once daily for 8 days
Number of subjects: 48
Study 36914591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36914652 — intervention group
Group type: EXPERIMENTAL
Intervention: Trotabresib (RP2D of 45 mg/day 4 days on/24 days off or 30 mg/day 3 days on/11 days off)
Number of subjects: 135
Study 36914809 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated abnormal FEF75% detected in 26 CF children at age 7.5 ± 4 years, remained an isolated abnormality for 2.5 ± 1.5 years.
Number of subjects: 39
Study 36914809 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated abnormal FEF75% detected in 13 children at age 11.7 ± 4.5 years, and abnormal FEF25-75% in 10 children at age 11.8 ± 5.3 years.
Number of subjects: 39
Study 36914828 — intervention group
Group type: COMPARATOR
Intervention: GB1211 5, 20, 50, 100, 200, or 400 mg (single ascending-dose)
Number of subjects: 78
Study 36914828 — intervention group
Group type: COMPARATOR
Intervention: GB1211 50 or 100 mg (multiple ascending-dose, twice daily for 10 days)
Number of subjects: 78
Study 36914828 — intervention group
Group type: COMPARATOR
Intervention: GB1211 (fasted state)
Number of subjects: 78
Study 36914828 — intervention group
Group type: COMPARATOR
Intervention: GB1211 (fed state)
Number of subjects: 78
Study 36914946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin in addition to standard treatment
Number of subjects: 351
Study 36914946 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 351
Study 36914957 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation
Number of subjects: 898
Study 36914957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 898
Study 36914957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin group
Number of subjects: 898
Study 36914957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 898
Study 36915009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles measured using a 15-plex human cytokine magnetic bead assay system.
Number of subjects: 40
Study 36915009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles including IL-6, IL-10, IL-15, MDC, GRO, sCD40 L, G-CSF, and FGF-2.
Number of subjects: 40
Study 36915062 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Number of subjects: 330
Study 36915062 — intervention group
Group type: COMPARATOR
Intervention: Macrogol/electrolytes
Number of subjects: 330
Study 36915075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 120
Study 36915106 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG (diaphragm)
Number of subjects: 29
Study 36915106 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG (ICM)
Number of subjects: 29
Study 36915106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-respiratory drive
Number of subjects: 29
Study 36915138 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile video interpreting plus standard interpreter access
Number of subjects: 55
Study 36915138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based educational modules plus standard interpreter access
Number of subjects: 55
Study 36915138 — intervention group
Group type: COMPARATOR
Intervention: Mobile video interpreting or educational modules (for providers with lower interpreter use after 9 months)
Number of subjects: 55
Study 36915138 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient comprehension (determined by comparing patient-reported to provider-documented visit diagnosis)
Number of subjects: 55
Study 36915146 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 91
Study 36915146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 36915184 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAH (Palforzia)
Number of subjects: 0
Study 36915182 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine administration during CPR
Number of subjects: 147
Study 36915199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal niclosamide
Number of subjects: 0
Study 36915199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and inhaled ciclesonide
Number of subjects: 0
Study 36915199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sotrovimab
Number of subjects: 0
Study 36915199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36915284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 36915284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36915287 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (increasing RUTF amount with increasing weight)
Number of subjects: 491
Study 36915287 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMA strategy (decreasing RUTF dose with increasing weight and MUAC)
Number of subjects: 491
Study 36915288 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT level >14 pg/mL
Number of subjects: 1739
Study 36915288 — intervention group
Group type: COMPARATOR
Intervention: hsTnT level ≤14 pg/mL
Number of subjects: 1739
Study 36915613 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-instructed therapy recommendations
Number of subjects: 661
Study 36915613 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiated therapies based on MTB recommendations
Number of subjects: 661
Study 36915613 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 661
Study 36915630 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 0
Study 36916022 — intervention group
Group type: EXPERIMENTAL
Intervention: Go&Grow (social exergame)
Number of subjects: 76
Study 36916022 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsocial exergame)
Number of subjects: 76
Study 36916707 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human acyl ghrelin (0.1 µg/kg/min)
Number of subjects: 31
Study 36916707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 36916707 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl ghrelin
Number of subjects: 31
Study 36916707 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl ghrelin antagonist D-Lys 3
Number of subjects: 31
Study 36917033 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal interstitial laser ablation (TPLA)
Number of subjects: 51
Study 36917033 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 51
Study 36917037 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal drug combination identified by knowledge graph
Number of subjects: 0
Study 36917123 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 159
Study 36917127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with care bundle including antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor.
Number of subjects: 37849
Study 36917127 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) without the care bundle.
Number of subjects: 37849
Study 36917127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with care bundle.
Number of subjects: 37849